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Background
Several health promoting effects have been attributed to
the polyphenol resveratrol including anti cancer, anti-
oxidant and anti-inflammatory activities.
Objective
We investigated the effects of resveratrol on LAD2 and
CD34
+-derived mast cell activation in comparison to the
known anti-allergy drug tranilast.
Methods
Degranulation was quantified by b hexosaminidase
assay, and cytokine, chemokine and cysteinyl leuko-
trienes (cysLT) expression was measured by real time
PCR and ELISA. Fura-2 Ca
2+ imaging was employed to
measure [Ca
2+]i.
Results
In LAD2 cells, both resveratrol and tranilast (10 ug/ml)
inhibited degranulation induced by mast cell activators
IgE/anti-IgE (39% and 19%, respectively; P<0.03), com-
pound 48/80 (9% and 6%), and substance P (23% and
28%; P<0.03). This may be attributable to modulation of
Ca
2+ levels, as resveratrol, and to a lesser extent tranilast,
attenuated substance P-dependent increases in [Ca
2+]i.
Resveratrol and tranilast blocked cytokine formation,
reducing substance P-induced TNF production (65%;
P=0.04 and 46%; P=0.09, respectively), but not MCP-1
production. Furthermore, resveratrol inhibited Fcepsi-
lonRI mediated production of cysLT by 31% compared to
control, whereas tranilast had no effect. The effects of
resveratrol on degranulation and release of cysLT were
more marked in human primary mast cells (HuMC)
(64% and 90% inhibition, respectively; P<0.05), and the
polyphenol was found to be significantly more efficacious
than tranilast in these cells.
Conclusions
Resveratrol inhibited mast cell function at the level of
degranulation, and cytokine and cysLT production, and
was comparable, and in some cases, more potent than
the anti-allergy drug tranilast. Thus resveratrol may be
an effective therapeutic agent for the treatment of aller-
gic disease.
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